GREENWICH, Conn., April 2, 2019 /PRNewswire-PRWeb/ -- OncoSynergy, Inc., a patient-focused oncology company committed
"I remember the exact moment at the lab bench, over a decade ago, when the concept for OS2966 began to take shape," said, Co-Founder and Chief Executive Officer of OncoSynergy, Shawn Carbonell, MD, PhD. "Now, with the accomplishment of this major milestone, OncoSynergy is officially a clinical-stage company. We are grateful for all the support from advisors, investors, collaborators, and, most recently, FDA."
OncoSynergy has partnered with Infuseon Therapeutics, a Cleveland Clinic spin-out, and Michael Vogelbaum, MD, PhD, Program Leader of Neuro-Oncology and Chief of Neurosurgery at Moffitt Cancer Center, and an inventor of the Infuseon Cleveland Multiport Catheter.
"I worked with Dr. Vogelbaum to design an innovative trial that made the most sense for patients and specifically addressed the challenges associated with treatment of glioblastoma," said Co-Founder and Chief Medical Officer of OncoSynergy, Anne-Marie Carbonell, MD. "We strived to build a collaborative relationship with FDA and I am grateful to have worked with an excellent and highly responsive review team."
OS2966 is the first-ever clinical-ready CD29 antibody under development for treatment of diverse cancers and targets fundamental interactions in the tumor microenvironment driving growth and treatment resistance. OncoSynergy has demonstrated the preclinical potential of OS2966 in the setting of treatment resistant solid and hematologic malignancies and in unique immunotherapy combinations.
Founding Scientific Advisory Board (SAB) member and eminent cell biologist at the Lawrence Berkeley National Laboratory, Mina J. Bissell, PhD commented, "For decades, I have asked tough biological questions to understand how cancer growth and progression are regulated at the level of tissue organization." Dr. Bissell continued, "It is exciting to see OncoSynergy translate this approach with OS2966, and take into account the critical context of the tumor microenvironment."
OS2966 has been awarded FDA Orphan Drug Designation in the treatment of glioblastoma and ovarian cancer. The target of OS2966, CD29 (also known as beta1 integrin), is overexpressed in the majority of cancers representing a tremendous opportunity in oncology.
Jean Pierre Bizzari, MD, former Celgene Group Head of Clinical Oncology Development, current Board Member of the European Organization of Research and Treatment of Cancer (EORTC), and member of OncoSynergy's SAB stated, "I have dedicated my professional life to helping patients by advancing novel cancer therapeutics. I am thrilled to see OncoSynergy advance their first-in-class therapeutic, OS2966, to the clinic for patients suffering from glioblastoma, a devastating brain cancer."
ABOUT ONCOSYNERGY – OncoSynergy, Inc. is a venture-backed, clinical-stage company founded in 2011 to provide definitive solutions for treatment-resistant and metastatic cancer through the development of a new class of oncology therapeutics, called Resistance Mechanism Inhibitors (RMIs). The lead RMI drug candidate, OS2966, is under development for the treatment of multiple advanced solid and hematological malignancies. OncoSynergy is a graduate of the prestigious JLABS @SSF life sciences incubator and recently relocated its headquarters to Greenwich, Connecticut.
To learn more, please visit OncoSynergy.com.
Subscribe to our Free Newsletters!